Cardiff Oncology (CRDF) Earnings Date, Estimates & Call Transcripts $2.90 -0.04 (-1.36%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cardiff Oncology Earnings Summary Upcoming Q4 Earnings DateMay. 1After Market ClosesEstimatedConsensus EPS (Nov. 7) -$0.27 Actual EPS (Nov. 7) -$0.25 Beat By $0.02 Actual Revenue (Nov. 7) $0.17MCardiff Oncology announced Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.25, which beat analysts' consensus estimates of -$0.27 by $0.02. Quarterly revenue was reported to be $0.17 million, above the consensus estimate of $0.13 million. With a trailing EPS of -$0.94, Cardiff Oncology's earnings are expected to grow next year, from ($0.99) to ($0.94) per share. Q3 2024 Earnings ResourcesQ3 2024 Earnings Report Press Release (8-K)CRDF Upcoming EarningsCardiff Oncology's Q1 2025 earnings is scheduled for Thursday, May 1, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportPowered by Get Cardiff Oncology Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCRDF Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRDF Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cardiff Oncology Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.28-$0.28-$0.28Q2 20251-$0.27-$0.27-$0.27Q3 20251-$0.31-$0.31-$0.31Q4 20251-$0.31-$0.31-$0.31FY 20254-$1.17-$1.17-$1.17Q1 20261-$0.26-$0.26-$0.26Q2 20261-$0.26-$0.26-$0.26Q3 20261-$0.28-$0.28-$0.28Q4 20261-$0.28-$0.28-$0.28FY 20264($1.08)($1.08)($1.08) Cardiff Oncology Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/1/2025(Estimated)-------11/7/2024--$0.27-$0.25+$0.02-$0.25$0.13M$0.17M8/8/2024Q2 2024-$0.25-$0.26 -$0.01-$0.26$0.12M$0.16M5/2/2024Q1 2024-$0.25-$0.22+$0.03-$0.22$0.11M$0.21M2/29/2024Q4 2023-$0.26-$0.21+$0.05-$0.21$0.08M$0.16M11/2/2023Q3 2023-$0.29-$0.22+$0.07-$0.22$0.08M$0.14M8/9/2023Q2 2023-$0.27-$0.25+$0.02-$0.25$0.08M$0.11M5/4/2023Q1 2023-$0.23-$0.25 -$0.02-$0.25$0.08M$0.08M Cardiff Oncology Earnings - Frequently Asked Questions When is Cardiff Oncology's earnings date? Cardiff Oncology has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 1st, 2025 based off last year's report dates. Learn more on CRDF's earnings history. Did Cardiff Oncology beat their earnings estimates last quarter? In the previous quarter, Cardiff Oncology (NASDAQ:CRDF) reported ($0.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.27) by $0.02. Learn more on analysts' earnings estimate vs. CRDF's actual earnings. How much revenue does Cardiff Oncology generate each year? Cardiff Oncology (NASDAQ:CRDF) has a recorded annual revenue of $683,000.00. How much profit does Cardiff Oncology generate each year? Cardiff Oncology (NASDAQ:CRDF) has a recorded net income of -$41.44 million. CRDF has generated -$0.94 earnings per share over the last four quarters. What is Cardiff Oncology's EPS forecast for next year? Cardiff Oncology's earnings are expected to grow from ($0.99) per share to ($0.94) per share in the next year. More Earnings Resources from MarketBeat Related Companies Xencor Earnings Results Anavex Life Sciences Earnings Results AbCellera Biologics Earnings Results Day One Biopharmaceuticals Earnings Results CureVac Earnings Results uniQure Earnings Results Praxis Precision Medicines Earnings Results Immunome Earnings Results Bicara Therapeutics Earnings Results Replimune Group Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock? This page (NASDAQ:CRDF) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRDF Stock Free CRDF Stock Alerts